Mangrove Partners’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Mangrove Partners’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51.3K	Hold	850,000	–	–	﹤0.01%	412
2025 Q4	$159K	Hold	850,000	–	–	0.01%	338
2025 Q3	$185K	Hold	850,000	–	–	0.01%	161
2025 Q2	$102K	Hold	850,000	–	–	0.01%	144
2025 Q1	$111K	Buy	+850,000	New	+$119K	0.01%	146

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Mangrove Partners's DMAAR Position: Q1 2026 in Review

Mangrove Partners held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q1 2026 at 850,000 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

Mangrove Partners first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $185K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

Mangrove Partners held 850,000 shares of Drugs Made In America Acquisition Corp Rights worth $51.3K as of Q1 2026.
Mangrove Partners left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q1 2026.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Mangrove Partners's portfolio in Q1 2026, its #412 holding.
Mangrove Partners first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
Mangrove Partners's Drugs Made In America Acquisition Corp Rights position peaked at $185K in Q3 2025.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.